Development of TDP-43 nuclear targeting aptamers for ALS/FTD
用于 ALS/FTD 的 TDP-43 核靶向适体的开发
基本信息
- 批准号:10558610
- 负责人:
- 金额:$ 8.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-01 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:Amyotrophic Lateral SclerosisAttenuatedAutopsyBenchmarkingBindingBiological AssayBroccoli - dietaryCell NucleusCellsChemistryChromatinComplexCytoplasmDNA BindingDataDevelopmentDiffuseDiseaseDissociationDoseDoxycyclineEnsureEnterobacteria phage MS2EvaluationEvolutionExonsFrontotemporal DementiaFutureGeneticGenetic TranscriptionHela CellsHistone H2BHistone H3Histone H4Immunofluorescence ImmunologicImmunoprecipitationInterventionLaboratoriesLengthLinkMALAT1 geneMS2 coat proteinMass Spectrum AnalysisMediatingMessenger RNAMicroRNAsMicroscopyMonitorMutationNeurodegenerative DisordersNeuronsNuclearNuclear ExportNuclear RNANucleotidesPathogenesisPathogenicityPathologicPatientsPlasmidsPoly ARNARNA BindingRNA SplicingRNA-Binding ProteinsRegulationResearchRibonucleoproteinsSmall Nucleolar RNAStructureSystemTDP-43 aggregationTestingTherapeuticTimeTransfectionU6 small nuclear RNAaptamerarmbeta Globinconfocal imagingcrosslinkcrosslinking and immunoprecipitation sequencingdesigneffective therapyfrontotemporal lobar dementia amyotrophic lateral sclerosisimprovedinhibitorinsightmRNA Precursornovelpreventprotein TDP-43prototyperesidencetherapy developmenttoolvector
项目摘要
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are closely-related, fatal
neurodegenerative diseases with considerable genetic and pathologic overlap. Postmortem analysis of more
than 97% of ALS cases and nearly half of FTD cases demonstrates nuclear clearance and cytoplasmic
aggregation of TDP-43, a primarily nuclear DNA- and RNA-binding protein that regulates pre-mRNA splicing.
Moreover, abundant evidence shows that the loss of TDP-43 nuclear function drives the evolution of many
aspects of ALS/FTD pathogenesis. This proposal seeks to build on recent data from our laboratory showing that
RNA critically tethers TDP-43 within the nucleus and limits its passive nuclear export. We propose to design a
novel RNA-based strategy to oppose TDP-43 nuclear export, guided by two observations: 1) TDP-43 nuclear
residence depends on its binding to GU-rich nuclear RNAs, and 2) small GU-rich RNA oligomers transfected into
live cells efficiently target and modulate the nuclear/cytoplasmic shuttling of TDP-43. Here, we will develop
bivalent RNA oligomers, termed TDP-43 nuclear targeting aptamers (TNTAs), to bind and retain the pool of free
TDP-43 that would otherwise diffuse out of the nucleus. The TNTA will consist of a reversible GU-rich TDP-43
targeting sequence (TTS), a linker, and a nucleus-targeting sequence (NTS), to anchor the TNTA-TDP-43
complex within stable nuclear ribonucleoprotein assemblies. Using the (GU)6 sequence as a starting point,
studies in aim 1 will further optimize the TTS motif, using the TDP-43 nuclear displacement assay as a readout
for successful TTS-TDP-43 interaction. Cells will be transfected by synthetic GU-rich RNAs (or poly-A, as a
negative control), and the nuclear exit of endogenous TDP-43 will be monitored by immunofluorescence with
automated confocal high-content microscopy. The direct TTS-TDP-43 interaction, its selectivity towards TDP-
43, and reversibility over time will then be evaluated to identify the optimal TTS sequence. In the second aim,
the nuclear retention sequences of several classes of endogenous nuclear RNAs will be tested to identify optimal
NTS sequences, that, when combined with the TTS can promote TDP-43 nuclear localization. Nuclear tethering
of TNTAs via the bacteriophage MS2-loop RNA-MCP system will be utilized as a positive control. TNTAs
combining the endogenous validated NTS linked to the GU-rich TTS will then be tested for activity in preventing
TDP-43 exit. Finally, the selectivity and reversibility of the TNTAs towards TDP-43 will be determined, and cryptic
exon incorporation will be evaluated to ensure no interference with TDP-43 nuclear function. Together, these
studies will identify and optimize a new tool to promote TDP-43 nuclear localization, to enable further therapy
development and improve our understanding of the regulation of TDP-43 nuclear/cytoplasmic shuttling.
肌萎缩侧索硬化症(ALS)和额颞叶痴呆症(FTD)是密切相关的,致命的
神经退行性疾病具有相当大的遗传和病理重叠。更多尸检分析
超过97%的ALS病例和近一半的FTD病例显示细胞核清除和细胞质清除。
TDP-43的聚集,TDP-43是一种主要调节前体mRNA剪接的核DNA和RNA结合蛋白。
此外,大量证据表明,TDP-43核功能的丧失驱动了许多细胞的进化。
ALS/FTD发病机制方面。这项建议旨在建立在我们实验室最近的数据基础上,这些数据表明,
RNA严格地将TDP-43束缚在细胞核内,并限制其被动核输出。我们建议设计一个
一种新的基于RNA的策略,以反对TDP-43核输出,由两个观察指导:1)TDP-43核
驻留取决于其与富含GU的核RNA的结合,和2)小的富含GU的RNA寡聚体转染到
活细胞有效地靶向并调节TDP-43的核/胞质穿梭。在这里,我们将开发
二价RNA寡聚体,称为TDP-43核靶向适体(TNTAs),结合并保留游离的
TDP-43会扩散出细胞核。TNTA将由一个可逆的富含GU的TDP-43组成。
靶向序列(TTS)、接头和核靶向序列(NTS),以锚定TNTA-TDP-43
在稳定的核核糖核蛋白装配中的复合物。使用(GU)6序列作为起始点,
目标1中的研究将进一步优化TTS基序,使用TDP-43核置换分析作为读数
用于成功的TTS-TDP-43交互。细胞将通过合成的富含GU的RNA(或多聚A,作为RNA的载体)转染。
阴性对照),并且内源性TDP-43的核出口将通过免疫荧光监测,
自动共聚焦高内涵显微镜。TTS-TDP-43的直接相互作用,其对TDP-43的选择性,
43,然后评估随时间的可逆性以识别最佳TTS序列。第二个目标,
将测试几类内源性核RNA的核保留序列,以鉴定最佳的
NTS序列,当与TTS组合时可以促进TDP-43核定位。核束缚
通过噬菌体MS 2-环RNA-MCP系统的TNTAs将被用作阳性对照。TNTAs
然后将与富含GU的TTS连接的内源性经验证的NTS组合,测试其在预防
TDP-43出口。最后,将确定TNTAs对TDP-43的选择性和可逆性,并将确定TNTAs对TDP-43的选择性和可逆性。
将评价外显子掺入以确保不干扰TDP-43核功能。所有这些
研究将确定和优化一种新的工具,以促进TDP-43核定位,使进一步的治疗,
开发和提高我们对TDP-43核/胞质穿梭调节的理解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lindsey Renae Hayes其他文献
Lindsey Renae Hayes的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lindsey Renae Hayes', 18)}}的其他基金
Development of TDP-43 nuclear targeting aptamers for ALS/FTD
用于 ALS/FTD 的 TDP-43 核靶向适体的开发
- 批准号:
10427644 - 财政年份:2022
- 资助金额:
$ 8.19万 - 项目类别:
RNA-based regulation of TDP-43 nuclear export in ALS/FTD
ALS/FTD 中基于 RNA 的 TDP-43 核输出调控
- 批准号:
10455671 - 财政年份:2021
- 资助金额:
$ 8.19万 - 项目类别:
RNA-based regulation of TDP-43 nuclear export in ALS/FTD
ALS/FTD 中基于 RNA 的 TDP-43 核输出调控
- 批准号:
10640898 - 财政年份:2021
- 资助金额:
$ 8.19万 - 项目类别:
RNA-based regulation of TDP-43 nuclear export in ALS/FTD
ALS/FTD 中基于 RNA 的 TDP-43 核输出调控
- 批准号:
10285495 - 财政年份:2021
- 资助金额:
$ 8.19万 - 项目类别:
FG-nucleoporins and nuclear transport disruption in C9ORF72-ALS/FTD
C9ORF72-ALS/FTD 中的 FG-核孔蛋白和核运输中断
- 批准号:
10237182 - 财政年份:2017
- 资助金额:
$ 8.19万 - 项目类别:
FG-nucleoporins and nuclear transport disruption in C9ORF72-ALS/FTD
C9ORF72-ALS/FTD 中的 FG-核孔蛋白和核运输中断
- 批准号:
9431708 - 财政年份:2017
- 资助金额:
$ 8.19万 - 项目类别:
FG-nucleoporins and nuclear transport disruption in C9ORF72-ALS/FTD
C9ORF72-ALS/FTD 中的 FG-核孔蛋白和核运输中断
- 批准号:
9980498 - 财政年份:2017
- 资助金额:
$ 8.19万 - 项目类别:
FG-nucleoporins and nuclear transport disruption in C9ORF72-ALS/FTD
C9ORF72-ALS/FTD 中的 FG-核孔蛋白和核运输中断
- 批准号:
9751978 - 财政年份:2017
- 资助金额:
$ 8.19万 - 项目类别:
相似海外基金
A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
- 批准号:
24K02286 - 财政年份:2024
- 资助金额:
$ 8.19万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
- 批准号:
2420924 - 财政年份:2024
- 资助金额:
$ 8.19万 - 项目类别:
Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
- 批准号:
10596047 - 财政年份:2023
- 资助金额:
$ 8.19万 - 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
- 批准号:
10742028 - 财政年份:2023
- 资助金额:
$ 8.19万 - 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
- 批准号:
BB/X017540/1 - 财政年份:2023
- 资助金额:
$ 8.19万 - 项目类别:
Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
- 批准号:
LP210301365 - 财政年份:2023
- 资助金额:
$ 8.19万 - 项目类别:
Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
- 批准号:
10730832 - 财政年份:2023
- 资助金额:
$ 8.19万 - 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
- 批准号:
10659841 - 财政年份:2023
- 资助金额:
$ 8.19万 - 项目类别:
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
- 批准号:
576545-2022 - 财政年份:2022
- 资助金额:
$ 8.19万 - 项目类别:
Idea to Innovation
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
- 批准号:
BB/V016067/1 - 财政年份:2022
- 资助金额:
$ 8.19万 - 项目类别:
Research Grant